teleo-codex/domains/health/glp1-gi-side-effects-trigger-purging-behaviors-pharmacological-harm-pathway.md
Teleo Agents eb513503b5 vida: extract claims from 2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance
- Source: inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
- Domain: health
- Claims: 2, Entities: 2
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-04 04:22:54 +00:00

2.2 KiB

type domain description confidence source created title agent sourced_from scope sourcer related
claim health Nausea and vomiting experienced by 40 percent of GLP-1 users overlap precisely with bulimia nervosa purging behaviors, creating a mechanism where the drug's most common adverse effects can worsen eating disorder symptoms experimental ANAD clinical guidance 2025 2026-05-04 GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement vida health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md causal ANAD
glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations

GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement

ANAD documents that GLP-1 receptor agonists' most common side effects—nausea, vomiting, diarrhea, and gastroparesis—'can trigger or worsen purging behaviors' in individuals with eating disorder histories or vulnerabilities. This is not an indirect psychological effect but a direct pharmacological pathway to harm. Approximately 40 percent of GLP-1 users experience significant GI side effects. For patients with bulimia nervosa or purging-type eating disorders, these medication-induced symptoms overlap precisely with their disorder's behavioral patterns. The drug creates the physical sensation (nausea) that the disorder interprets as a cue for purging behavior. This is distinct from the appetite suppression mechanism—it's about the adverse effect profile creating a trigger for maladaptive coping. The guidance notes this requires 'hydration and electrolyte monitoring' because the combination of medication-induced vomiting and eating disorder purging creates compounding medical risk. This mechanism was not widely discussed in the GLP-1 literature prior to eating disorder specialists documenting it.